docetaxel

Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
QoL prognostic in mCRPC patients on salvage therapyClinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Adjuvant chemo well tolerated in high-risk PCa patientsA Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
CRPC document aids in complex decisionsIn its current iteration, the AUA's CRPC guideline contains 20 statements relating to treatments for six index patients defined by the presence or absence of metastatic disease, presence and degree of symptoms, ECOG performance status, and prior treatment with docetaxel (Taxotere) along with two statements on the use of preventive treatments for bone health.
New Products: Single-use ureteroscope, new FDA Approvals for RCC treatment, and an App that helps IC, chronic prostatitis patientsCheck out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.
FDA expands use for lung cancer drugSoon after the FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC), it approved Opdivo (nivolumab) for an expanded use – to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Upfront chemo called ‘standard’ in hormone-naïve PCa
Upfront chemo called ‘standard’ in hormone-naïve PCaDocetaxel (Taxotere) added to standard hormone therapy extended mean survival by about 10 months, according to a recent large-scale study.
Upfront chemo for PCa? Yes, but…With conflicting data, should docetaxel be used up front in newly diagnosed metastatic disease?
Continued advances in cancer outcomes unveiled at ASCOLeading cancer drugs reduced the risk of death by half for people with lung cancer and assisted patients with HER2-positive breast cancer live longer without the disease recurring. The findings were just two of the numerous important study results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago, Ill., this week.
mCRPC advances come with choices, challengesIn this article, Robert A. Dowling, MD, examines some of the practice-related implications of the rapid change in the management of patients with advanced prostate cancer.